Stage III Uterine Sarcoma: Clinical Trials

11 trials for Stage III Uterine Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 terminated. 8 Phase 2, 2 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 28Completed 8
Phase 12Completed 2
Not applicable1Terminated 1

Follow Stage III Uterine Sarcoma: new trials by email Literature Review of Stage III Uterine Sarcoma trials Research Report on Stage III Uterine Sarcoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
behavioral, psychological or informational intervention - Ovarian Sarcoma, Ovarian Stromal Cancer
Phase 2CompletedOhio State University Comprehensive Cancer Center1002010-10-012018-05-30
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
Medical Chart Review, Questionnaire Administration - Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma
CompletedGynecologic Oncology Group7782010-07-012018-04-12
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Phase 1CompletedUniversity of Southern California192010-06-012016-06-13
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)782010-06-012018-08-15
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
therapeutic angiotensin-(1-7), laboratory biomarker analysis - Bone Cancer, Chondrosarcoma
Phase 2CompletedWake Forest University Health Sciences202009-10-012018-07-05
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
stereotactic radiosurgery, quality-of-life assessment - Fallopian Tube Cancer, Ovarian Sarcoma
Phase 2CompletedCase Comprehensive Cancer Center502009-05-012013-11-28
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)172008-02-012018-06-29
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer
Phase 2CompletedNational Cancer Institute (NCI)632006-09-012015-12-07
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
sorafenib tosylate - Adult Angiosarcoma, Adult Epithelioid Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1472005-09-012014-05-23
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
sorafenib tosylate - Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)562005-02-012015-11-20
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
EF5, motexafin lutetium, pharmacological study - Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
Not applicableTerminatedNational Cancer Institute (NCI)302004-05-012013-01-16

Narrower conditions

Carcinoma, Ovarian Epithelial (5)  ·  Sarcoma (5)  ·  Fallopian Tube Neoplasms (4)  ·  Uterine Cervical Neoplasms (4)  ·  Endometrial Neoplasms (3)  ·  Histiocytoma, Malignant Fibrous (3)  ·  Leiomyosarcoma (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Chondrosarcoma (2)  ·  Dermatofibrosarcoma (2)  ·  Fibrosarcoma (2)  ·  Gastrointestinal Stromal Tumors (2)  ·  Hemangiosarcoma (2)  ·  Liposarcoma (2)

Broader conditions

Neoplasms (9)  ·  Neoplasms by Histologic Type (9)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Genital Diseases (7)  ·  Genital Diseases, Female (7)  ·  Genital Neoplasms, Female (7)  ·  Neoplasms by Site (7)  ·  Urogenital Diseases (7)  ·  Urogenital Neoplasms (7)  ·  Neoplasms, Glandular and Epithelial (6)  ·  Adnexal Diseases (5)  ·  Carcinoma (5)  ·  Endocrine Gland Neoplasms (5)  ·  Endocrine System Diseases (5)

Interventions

Sorafenib (2)  ·  2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)  ·  HhAntag691 (1)  ·  Radiosurgery (1)  ·  Sirolimus (1)  ·  Vinorelbine (1)  ·  aflibercept (1)  ·  angiotensin I (1-7) (1)  ·  motexafin lutetium (1)  ·  saracatinib (1)  ·  temsirolimus (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  Case Comprehensive Cancer Center (1)  ·  Gynecologic Oncology Group (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  University of Southern California (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (11)  ·  Canada (3)

Top investigators

Agustin Garcia (1)  ·  Amit Oza (1)  ·  Gini Fleming (1)  ·  Kristen M. Carpenter, Ph.D (1)  ·  Margaret von Mehren (1)  ·  Mrinal Gounder (1)  ·  Robert DeBernardo, MD (1)  ·  Robert Maki (1)  ·  Sandra Brooks (1)  ·  Stephen Michael Hahn (1)  ·  William Petty (1)

Results publications

PMID 25937529, PMID 40082377

NIH funding

N01CM62203 (3), N01CM62201 (2), N01CM62206 (2), P30CA008748 (2), N01CM62209 (1), P01CA087971 (1), R21CA149675 (1), U01CA069856 (1), U10CA101165 (1)